These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27846654)

  • 41. Response to commentaries.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
    [No Abstract]   [Full Text] [Related]  

  • 42. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 44. "Legal highs" - new players in the old drama.
    Zawilska JB
    Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing misuse of novel psychoactive substances.
    Solomon D; Grewal P; Taylor C; Solomon B
    Nurs Times; 2014 May 28-Jun 3; 110(22):12-5. PubMed ID: 24984370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Drugs of Abuse and Withdrawal Syndromes.
    Andrabi S; Greene S; Moukaddam N; Li B
    Emerg Med Clin North Am; 2015 Nov; 33(4):779-95. PubMed ID: 26493523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stimulant and Designer Drug Use: Primary Care Management.
    Klega AE; Keehbauch JT
    Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current situation and issues for analyzing illegal drug products].
    Hasegawa T; Takahashi K; Saijo M; Fukiwake T; Motoki Y
    Yakugaku Zasshi; 2013; 133(1):7-11. PubMed ID: 23292013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Synthetic drugs: the new low-cost landscape of drugs].
    Karila L; Petit A; Cottencin O; Coscas S; Reynaud M
    Rev Prat; 2012 May; 62(5):664-6. PubMed ID: 22730798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical complications of new synthetic drugs].
    Djezzar S; Batisse A
    Rev Prat; 2018 Jan; 68(1):79-83. PubMed ID: 30840395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.
    Smith CD; Robert S
    Clin Med (Lond); 2014 Aug; 14(4):409-15. PubMed ID: 25099844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential effects of synthetic psychoactive cathinones and amphetamine stimulants on the gut microbiome in mice.
    Angoa-Pérez M; Zagorac B; Winters AD; Greenberg JM; Ahmad M; Theis KR; Kuhn DM
    PLoS One; 2020; 15(1):e0227774. PubMed ID: 31978078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alarm over synthetic cannabinoids.
    Underwood E
    Science; 2015 Jan; 347(6221):473. PubMed ID: 25635070
    [No Abstract]   [Full Text] [Related]  

  • 56. The Growing Problem of New Psychoactive Substances (NPS).
    Madras BK
    Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Life (and death) in Pink: The dangerous rise of synthetic opioids in the new psychoactive substances panorama.
    Santacroce R; Bosio E; Ferrero F; Mignone M
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):225-226. PubMed ID: 29249554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The environmental impact and adverse health effects of the clandestine manufacture of methamphetamine.
    Irvine GD; Chin L
    NIDA Res Monogr; 1991; 115():33-46. PubMed ID: 1758481
    [No Abstract]   [Full Text] [Related]  

  • 60. Shifting from an illegal-drug policy to a psychoactive substance policy.
    van der Linde F
    Soz Praventivmed; 2006; 51(3):128-9. PubMed ID: 17191533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.